<DOC>
	<DOCNO>NCT01662726</DOCNO>
	<brief_summary>This study investigate effect new hormone treatment breast cancer call Irosustat . Seventy percent breast cancer post-menopausal wome rely oestrogen grow therefore likely respond hormone therapy . Irosustat block different pathway steroid synthesis Aromatase , reduce way oestrogen level body . As less oestrogen reach breast cancer , grow slowly stops grow altogether . IPET recruit postmenopausal woman early , hormone sensitive , treatment naive breast cancer receive 40mg Irosustat daily 2 week . The effect Irosustat breast cancer evaluate PET scan ( Positron Emission Tomography ) use radioactive substance call FLT tracer . The scan perform PET-CT scanner combine PET scan CT scan ( Computer Tomography ) one scan . This type scan show body tissue work , well look like . FLT-PET scan perform follow treatment Irosustat . As cancer cell grow faster normal cell around , take radioactive substance , stand clearly scan . If Irosustat slow cancer growth , cancer take less tracer . Blood sample take regular interval assess new drug body safety tolerability Irosustat assess . The study incorporate translation aspects/endpoints base collection tumour biopsy treatment Irosustat although later biopsy mandatory .</brief_summary>
	<brief_title>A Study Assess Ability Novel Endocrine Treatment Breast Cancer , Irosustat , Slow Down Cancer Growth</brief_title>
	<detailed_description>Objectives Primary : To assess change [ 18F ] fluorothymidine ( FLT ) uptake use Positron Emission Tomography ( PET ) follow 2 week Irosustat treatment patient early , treatment naïve , oestrogen receptor positive ( ER +ve ) breast cancer Secondary : To assess : 1 . Pharmacodynamic profile Irosustat 2 . Safety tolerability Irosustat Study Population : Postmenopausal woman early , treatment naïve , ER +ve breast cancer</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Written inform consent participate trial 2 . 18 year age old 3 . Histologically confirm ER +ve breast cancer ( Allred ≥ 3 ) 4 . Any HER2 status 5 . Tumour measure ≥ 15mm long diameter ultrasound ( US ) examination 6 . Postmenopausal woman define one follow criterion : Amenorrhoea &gt; 12 month time diagnosis intact uterus OR , prior bilateral oophorectomy OR , FSH level within postmenopausal range ( per local practice ) woman age &lt; 55years undergone hysterectomy OR , FSH level within postmenopausal range ( per local practice ) woman age &lt; 55 year Hormone Replacement Therapy ( HRT ) within last 12 month therefore amenorrhoeic 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 8 . Adequate bone marrow function define Hb ≥ 10 g/dl , WBC ≥ 3.0 x109 , PLT ≥ 100 x109/L . Adequate renal function define serum creatinine ≤ 1.5 x ULN . Adequate liver function define total bilirubin ≤ 1.5 ULN ( patient Gilbert 's syndrome exempt ) , either ALT AST ≤ 1.5 ULN ALP ≤ 1.5 ULN 1 . Locally advanced/inoperable breast cancer 2 . Clinical evidence metastatic disease 3 . Diffuse inflammatory tumour 4 . Any history invasive malignancy within 5 year start study treatment ( adequately treat basal cell carcinoma squamous cell carcinoma skin cervical carcinoma situ ) 5 . Evidence bleed diathesis PTT PT ≤ 1.5 x upper limit normal 6 . Concomitant use ( define use within 4 week prior entry ) HRT oestrogencontaining medication supplement ( include vaginal oestrogen phytoestrogens ) 7 . Previous use oestrogen implant ANY time . 8 . Concomitant use : Rifampicin CYP2C 3A inducer rifabutin , rifapentine , carbamazepine , phenobarbital , phenytoin St. John 's Wort Systemic carbonic anhydrase inhibitor 9 . Any following cardiac criterion : Mean rest correct QT interval ( QTcf ) &gt; 450 m obtain 3 electrocardiogram ( ECGs ) Any clinically important abnormality rhythm , conduction morphology rest ECG e.g . complete leave bundle branch block , third degree heart block Any factor increase risk QTc prolongation risk arrhythmic event heart failure , hypokalaemia , congenital long QT syndrome , family history long QT syndrome unexplained sudden death 40 year age concomitant medication know prolong QT interval 10 . Uncontrolled abnormality serum potassium , sodium , calcium magnesium level 11 . Evidence uncontrolled active infection 12 . Evidence significant medical condition laboratory finding , opinion investigator , make undesirable patient participate trial 13 . Subjects unable lie flat fit scanner 14 . Patients occupational monitoring radiation exposure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>